HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients....
Popular Japanese Boy Band King & Prince Delivers a Captivating Overseas Performance TAIPEI, Feb. 4, 2025 /PRNewswire/ -- The 2025 TTV SUPER STAR, which...
SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sojern, the leading digital marketing platform built for travel, is excited to announce the launch of the "State...